Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (388)
- Scheduling (national classification system) (171)
- Safety monitoring and information (27)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
770 result(s) found, displaying 51 to 75
-
Meeting statementsCommunique from the 2nd meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 1 May 2025
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #47 meeting held in June 2025
-
Meeting statementsMeeting statement from the 16th Consumer Working Group (CWG) meeting that took place on 25 March 2025.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 November 2024
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsRead the meeting statement from the meeting of the Advisory Committee on Medical Devices (ACMD).
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #47 and Joint ACMS-ACCS #40 meetings held in June 2025
-
Corporate reportsFind out about the seasonal influenza vaccines available for the 2025 southern hemisphere season.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsClarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
Meeting statementsRead the meeting statement from 13 February 2025 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Corporate reportsDetailed statistical information on Therapeutic Goods Administration performance in pre- and post-market activities.
-
Corporate reportsThis report provides information about our regulatory performance for the 2023-24 financial year.
-
Scheduling decisions (interim)Interim decisions on proposed amendments to the Poisons Standard closing 4 April 2025
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 49 for meeting held 2 October 2024
-
Meeting statementsAdvisory Committee on Vaccines Statement 51 for meeting held 5 February 2025
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 50 held 4 December 2024
-
Meeting statementsMeeting statement from the 15th Medical Devices Consumer Working Group (CWG) meeting that took place on 8 November 2024.
-
Scheduling decisions (interim)We have reopened the consultation on the interim decision regarding IV potassium in recognition of the broad impact of the proposed changes
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Corporate reportsThis report provides an overview of pharmacovigilance inspection deficiencies in 2022, including a comparison to results from previous reporting periods.
-
Corporate reportsThe findings will inform the need for any risk management actions to ensure public safety.
-
Scheduling decisions (final)Publication of the decisions made by a delegate of the Secretary in relation to to nicotinic acid.